Bioanalysis of biomarkers for drug development
Application of commercial research-grade biomarker assays in drug development: is it time to create ‘pharmaceutical-grade’ kits?
Important considerations for quantitation of small-molecule biomarkers using LC–MS
A novel class of biomarkers gives hope for drug discovery in the treatment of neurodegenerative diseases
National Cancer Institute licenses GVK Biosciences’ Online Biomarker Database
Industry and academia collaborate on lipidomics
Eckert and Ziegler Strahlen acquire US-based Vitalea Science, Inc.
Joint venture between MedImmune LLC and WuXi AppTec announced
Recommendations on biomarker bioanalytical method validation by GCC
Prandial ghrelin attenuation provides evidence that des-acyl ghrelin may be an artifact of sample handling in human plasma
Defining putative glycan cancer biomarkers by MS
Flow cytometry: a flexible tool for biomarker research
Use of PD biomarkers to drive dose selection and early clinical decision making
Genomic biomarkers for patient selection and stratification: the cancer paradigm
Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics
Relative quantification of biomarkers using mixed-isotope labeling coupled with MS
Acknowledgements
Erratum